Leukemia Research Reports 1 (2012) A2–A5
Contents lists available at SciVerse ScienceDirect
Leukemia Research Reports journal homepage: www.elsevier.com/locate/lrr
Editorial
Leukemia Research Reports: Guide for authors
Leukemia Research Reports is an open access, international journal which delivers timely information online to all health care professionals involved in basic and/or applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. It does this by rapidly publishing a range of peerreviewed short form papers, including brief communications, case reports, letters to the Editors, images, and debate articles. The Editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies. Leukemia Research Reports’ coverage encompasses the application of oncogenes, genomics (gene expression profiles and microRNAs), proteomics, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition articles are solicited on the rapidly growing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms. Publishing policy—All articles will be peer reviewed and if accepted for publication in the Journal, Authors will be notified of this decision and at the same time requested to pay an Article Processing Fee of US$ 600/EUR 458/JPY 46,638 (exclusive of VAT/ Sales Tax). Following payment of this fee, articles will be made universally available at no further charge through ScienceDirect and through the Journal’s own website www.lrreports.com. Submission of Manuscripts – All Manuscripts and Material should be submitted on-line via EES-http://ees.elsevier.com/lrr/ Please refer to the ‘Tutorial for Authors’ located on the EES site for guidance on the electronic submission process. All published papers containing research data are subject to peer-review. Submission of an article implies that the work described has not been published previously and will not be simultaneously submitted or published elsewhere (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the Publisher. These guidelines generally follow the ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals’. The complete document appears at -http://www.icmje.org. Submitting an Article—Articles should be submitted online at -http://ees.elsevier.com/lrr/ and the instructions on the site should be closely followed. Authors may submit manuscripts and track their progress to final decision. 2213-0489/$ - see front matter & 2012 Published by Elsevier Ltd. http://dx.doi.org/10.1016/j.lrr.2012.11.002
Types of Contribution—All articles are limited by word count and the number of references. Word count limits do not include the abstract, references, acknowledgment, figures or tables, or their captions. Brief Communications include an abstract; the total word count should not exceed 1200 words, a maximum of 10 references and up to 4 figures and/or tables. Case Reports include an abstract; they should not exceed 1200 words, a maximum of 10 references and an optional 1–2 figures and/or tables. Letters to the Editor should clearly indicate the purpose of the letter by a brief striking title; they should include an abstract and should not exceed 1200 words, up to 5 references and an optional 1–2 figures and/or tables. Debate and Controversies—the journal welcomes opinion pieces on research and clinical topics in leukemia. Debate & Controversies articles should include an abstract, should not exceed 1200 words, plus a maximum of 5 references and 1 figure or table. Images—authors are encouraged to submit images for publication. These should be accompanied by a title and a caption that explains the significance of the image. In addition to ‘still life ‘ images, authors may submit video files. For full details of artwork formats see below. Meeting Perspectives are reports on one or several sessions of Congress, Workshops or Symposia (also closed ones). Such papers should not exceed 1200 words, 5 references and up to 2 figures and/or tables. Comments on Published Papers are comments on a prior published paper. Mention the title in both the Cover Letter and the References. This paper does not have an abstract and should not exceed 1200 words; limit 3 references and optional 1–2 figures and/or tables. Comments that seek to address an error in a previous paper are exempt from the Article Processing Fee if accepted for publication. Preparation of Manuscripts 1. Covering letter: This is a letter stating that you wish to submit your paper to Leukemia Research Reports. Please include the title, and signature of corresponding author. Also include details of any previous version. 2. All contributions must be 1.5 spaced except the references which are single spaced with a space between each reference. 3. Manuscripts submitted for publication should be written concisely and clearly. Manuscripts will only be accepted when they are written in an acceptable standard of English (American or British usage is accepted, but not a mixture of these). Authors whose native language is not English are strongly advised to have
Editorial / Leukemia Research Reports 1 (2012) A2–A5
their manuscripts be checked by an English-speaking colleague prior to submission or to submit them for language editing (see below for more details). Either the Concise Oxford Dictionary or Webster’s New International Dictionary may be used as a standard for English spelling. 4. The manuscript should be organized in the following sequence: All manuscripts must have a title page which is Page 1 of your manuscript. Note the Title should be clear, descriptive and less than 20 words long. Avoid non-specific phrases such as ‘A study ofy’ or ‘The effects ofy’. Do not give the title a numbered subtitle or series number. The title page is the first page of the paper and must contain the following: title name of authors (listed as, first name last name academic degree then superscript the institutional code); institutional has superscript code (1, 2, 3,y), Department ofy, institution, city and country; the Corresponding Author. Note: No positions like Dr., Professor, or Faculty of, we use academic degrees only. Role of Corresponding Author: Please note there is only one corresponding author of the manuscript. The corresponding author is the one that submits the manuscript and is displayed on the Title Page of the manuscript. They have the duty to ensure that all of the named authors have seen and approved the original manuscript and subsequent revisions. Each author should have participated sufficiently in the work to take public responsibility for the content. The corresponding author should also ensure that those who have contributed to the research are acknowledged appropriately either as a co-author or in the Acknowledgments. In addition, the corresponding author has the prime responsibility for ensuring the paper is correctly prepared according to the Guide for Authors. Submitted manuscripts not complying with the Guide for Authors may be returned to the authors for revision. Word Count: does not include the references, acknowledgment, figures and tables. Abstract: The abstract should be clear, descriptive and less than 100 words. Keywords—Keywords are index terms or descriptions for information retrieval systems, and a maximum of five should be provided. Words selected should reflect the essential topics of the article and may be taken from both the title and the text. Abbreviations and units: Generally, avoid abbreviations in the Title and abbreviating single words. Otherwise explain all abbreviations at first mention in the abstract and text, except for: DNA, RNA, AIDS, and HIV. Standard SI abbreviations for units do not need to be spelled out. Brief Communications should include an Introduction, Materials and Methods, Results and Discussion sections. Case Reports and Letters to the Editor do not need to include these divisions. Introduction: This should give the reasons for doing the work. As this is a specialist journal a detailed review of the literature is not necessary. The introduction should preferably conclude with a final paragraph stating concisely and clearly the aims and objectives of the investigation. Materials and Methods: A full technical description of a method should be given in detail only when the method is new. Results: This need only report results of representative experiments illustrated by tables and figures. Use well-known statistical tests in preference to obscure ones. Consult a statistician or a statistics text for detailed advice. Discussion (including Conclusions): This section must not recapitulate results but should relate the authors’ experiments to other work and give their conclusions, which may be given in a subsection headed after called Conclusions. References: References are numbered. All publications cited in the text should be presented in a list of references following the text of the manuscript. In the text refer to references by a number
A3
in square brackets on the line (e.g. Since Peterson [1]), and the full reference should be given in a numerical list at the end of the paper. References should be given in the following form: 1. Latagliata R, Concetta Petti M, Mandelli F. Acute myeloid leukemia in the elderly: ‘per aspera ad astra’? Leukemia Res 1999;23:603– 613. 2. Alfrey V. The isolation of subcellular components. In: Brachet J, Mirsky AE, editors. The cell, biochemistry, physiology, morphology I. New York: Academic Press, 1959. p. 200. Note: Authors are strongly encouraged to check the accuracy of each reference against its original source. Work accepted for publication but not yet published should be referred to as ‘in press’. Authors should provide evidence (such as a copy of the letter of acceptance). References concerning unpublished data, theses, and ‘personal communications’ should not be cited in the reference list but may be mentioned in the text. Do not only put the first author et al. list all authors. 5. Acknowledgments should be organized in the following sequence. Acknowledgments—All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgments section. E.g. those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair that provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance. Role of the funding source—All sources of funding should be declared. Authors should declare the role of study sponsors, if any, in the study design, collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. Authors’ Contributions—All authors should have made substantial contributions to the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data. (2) drafting the article or revising it critically for important intellectual content. (3) final approval of the version to be submitted. For authors we use initials and if there is more than one author that does the same function put them together. Note: If there is more than one author that contributed equally to the work it goes in this section not on the title page. Conflict of Interest—All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. E.g. potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/ registrations, and grants or other funding. If there no conflicts of interest exist this must be stated. Please see the Elsevier website for further information http://www.elsevier.com/wps/find/ authorsview.authors/conflictsofinterest. 6. Figures and Figure Legends—Figures should be cited consecutively in the text. Full details for the electronic submission of artwork can be obtained from http://www.elsevier.com/artwor kinstructions. All figures have to be uploaded in EES separately. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions. Type the figure legends in order in one word document and starting with the words figure legends; limit 40 words or less. Spacing is 1.5 and if more than one page put a page number in the footer. 7. Table and Table Legends—Tables should be cited consecutively in the text. Type tables on separate pages with a title. Avoid white spaces in the table by using footnotes, and ensure all symbols or abbreviation are explained. Take care to distinguish between ‘zero’ and ‘not done’ as an entry in the table. Tables are uploaded separately.
A4
Editorial / Leukemia Research Reports 1 (2012) A2–A5
Type the table legends in order in one word document and starting with the words table legends. Spacing is 1.5 and if more than one page put a page number in the footer. Footnotes: Footnotes should only be used to provide addresses of authors or to provide explanations essential to the understanding of Tables. 8. Supplementary Data—As Leukemia Research Reports focuses on short papers, Supplementary Data files are not accepted. Ethics—Identifying information, including patients images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission. Drug names—Use generic names for drugs. Commercial names may be included in parentheses at first mention in the text. Complicated drug names or regimens may be abbreviated, with the abbreviation in parentheses after first mention. Revised Manuscript—All manuscripts are peer-reviewed. On receipt of the first decision letter authors should send their revised manuscript as soon as possible in order to ensure that the scientific content of their manuscript is timely and up to date. The revised paper must be submitted without tracking or highlights and 1.5 spaced. A Revision Letter must contain detailed responses to the reviewers and indicate where in the letter you changed the text. Author Names—This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts: Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include the following: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, and letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum. Copyright—Upon acceptance of an article, authors will be asked to sign a Journal Publishing Agreement. This includes details of the rights that you retain as author (for more information on this and copyright see http://www.elsevier.com/wps/find/ authorsview.authors/authorsrights). An e-mail will be sent to the corresponding author confirming receipt of the manuscript
together with a Journal Publishing Agreement form. Following signature of this form and payment of the Author Fee, case reports will be made universally accessible through -ScienceDirect and through the Journal’s own website, www.lrreports.com. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases; contact Elsevier s Rights Department, Philadelphia, PA, USA: Tel. (þ1) 215 238 7869; Fax (þ1) 215 238 2239; e-mail [email protected]. Requests may also be completed online via the Elsevier homepage (http://www.elsevier.com/locate/permissions). Proofs—One set of page proofs in PDF format will be sent by email to the corresponding author. Elsevier now sends PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 available free from -http://www.adobe. com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: -http://www.adobe. com/products/acrobat/acrrsystemreqs.html#70win. If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received. Language services—Authors who require information about language editing and copyediting services pre- and postsubmission should visit -http://webshop.elsevier.com/language services or our customer support site at -http://support.elsevier. com for more information. Enquiries—Authors can keep a track on the progress of their accepted article, and set up e-mail alerts informing them of changes to their manuscript’s status, by using the ‘Track a Paper’ feature at: http://www.elsevier.com/trackarticle. For privacy, information on each article is password-protected. The author should key in the ‘Our Reference’ code (which is in the letter of acknowledgment sent by the publisher on receipt of the accepted article) and the name of the corresponding author. In case of problems or questions, authors may contact the Author Service Department, E-mail: [email protected] Offprints—The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. & 2012 Elsevier Ltd. All rights reserved—This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd. Please click on User Rights for a summary of how articles published in Leukemia Research Reports can be utilized. Notice—No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or
Editorial / Leukemia Research Reports 1 (2012) A2–A5
operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical)
A5
standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. Thank you for considering Leukemia Research Reports for your submission.
Contents lists available at SciVerse ScienceDirect
Leukemia Research Reports journal homepage: www.elsevier.com/locate/lrr
Editorial
Leukemia Research Reports: Guide for authors
Leukemia Research Reports is an open access, international journal which delivers timely information online to all health care professionals involved in basic and/or applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. It does this by rapidly publishing a range of peerreviewed short form papers, including brief communications, case reports, letters to the Editors, images, and debate articles. The Editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies. Leukemia Research Reports’ coverage encompasses the application of oncogenes, genomics (gene expression profiles and microRNAs), proteomics, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition articles are solicited on the rapidly growing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms. Publishing policy—All articles will be peer reviewed and if accepted for publication in the Journal, Authors will be notified of this decision and at the same time requested to pay an Article Processing Fee of US$ 600/EUR 458/JPY 46,638 (exclusive of VAT/ Sales Tax). Following payment of this fee, articles will be made universally available at no further charge through ScienceDirect and through the Journal’s own website www.lrreports.com. Submission of Manuscripts – All Manuscripts and Material should be submitted on-line via EES-http://ees.elsevier.com/lrr/ Please refer to the ‘Tutorial for Authors’ located on the EES site for guidance on the electronic submission process. All published papers containing research data are subject to peer-review. Submission of an article implies that the work described has not been published previously and will not be simultaneously submitted or published elsewhere (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the Publisher. These guidelines generally follow the ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals’. The complete document appears at -http://www.icmje.org. Submitting an Article—Articles should be submitted online at -http://ees.elsevier.com/lrr/ and the instructions on the site should be closely followed. Authors may submit manuscripts and track their progress to final decision. 2213-0489/$ - see front matter & 2012 Published by Elsevier Ltd. http://dx.doi.org/10.1016/j.lrr.2012.11.002
Types of Contribution—All articles are limited by word count and the number of references. Word count limits do not include the abstract, references, acknowledgment, figures or tables, or their captions. Brief Communications include an abstract; the total word count should not exceed 1200 words, a maximum of 10 references and up to 4 figures and/or tables. Case Reports include an abstract; they should not exceed 1200 words, a maximum of 10 references and an optional 1–2 figures and/or tables. Letters to the Editor should clearly indicate the purpose of the letter by a brief striking title; they should include an abstract and should not exceed 1200 words, up to 5 references and an optional 1–2 figures and/or tables. Debate and Controversies—the journal welcomes opinion pieces on research and clinical topics in leukemia. Debate & Controversies articles should include an abstract, should not exceed 1200 words, plus a maximum of 5 references and 1 figure or table. Images—authors are encouraged to submit images for publication. These should be accompanied by a title and a caption that explains the significance of the image. In addition to ‘still life ‘ images, authors may submit video files. For full details of artwork formats see below. Meeting Perspectives are reports on one or several sessions of Congress, Workshops or Symposia (also closed ones). Such papers should not exceed 1200 words, 5 references and up to 2 figures and/or tables. Comments on Published Papers are comments on a prior published paper. Mention the title in both the Cover Letter and the References. This paper does not have an abstract and should not exceed 1200 words; limit 3 references and optional 1–2 figures and/or tables. Comments that seek to address an error in a previous paper are exempt from the Article Processing Fee if accepted for publication. Preparation of Manuscripts 1. Covering letter: This is a letter stating that you wish to submit your paper to Leukemia Research Reports. Please include the title, and signature of corresponding author. Also include details of any previous version. 2. All contributions must be 1.5 spaced except the references which are single spaced with a space between each reference. 3. Manuscripts submitted for publication should be written concisely and clearly. Manuscripts will only be accepted when they are written in an acceptable standard of English (American or British usage is accepted, but not a mixture of these). Authors whose native language is not English are strongly advised to have
Editorial / Leukemia Research Reports 1 (2012) A2–A5
their manuscripts be checked by an English-speaking colleague prior to submission or to submit them for language editing (see below for more details). Either the Concise Oxford Dictionary or Webster’s New International Dictionary may be used as a standard for English spelling. 4. The manuscript should be organized in the following sequence: All manuscripts must have a title page which is Page 1 of your manuscript. Note the Title should be clear, descriptive and less than 20 words long. Avoid non-specific phrases such as ‘A study ofy’ or ‘The effects ofy’. Do not give the title a numbered subtitle or series number. The title page is the first page of the paper and must contain the following: title name of authors (listed as, first name last name academic degree then superscript the institutional code); institutional has superscript code (1, 2, 3,y), Department ofy, institution, city and country; the Corresponding Author. Note: No positions like Dr., Professor, or Faculty of, we use academic degrees only. Role of Corresponding Author: Please note there is only one corresponding author of the manuscript. The corresponding author is the one that submits the manuscript and is displayed on the Title Page of the manuscript. They have the duty to ensure that all of the named authors have seen and approved the original manuscript and subsequent revisions. Each author should have participated sufficiently in the work to take public responsibility for the content. The corresponding author should also ensure that those who have contributed to the research are acknowledged appropriately either as a co-author or in the Acknowledgments. In addition, the corresponding author has the prime responsibility for ensuring the paper is correctly prepared according to the Guide for Authors. Submitted manuscripts not complying with the Guide for Authors may be returned to the authors for revision. Word Count: does not include the references, acknowledgment, figures and tables. Abstract: The abstract should be clear, descriptive and less than 100 words. Keywords—Keywords are index terms or descriptions for information retrieval systems, and a maximum of five should be provided. Words selected should reflect the essential topics of the article and may be taken from both the title and the text. Abbreviations and units: Generally, avoid abbreviations in the Title and abbreviating single words. Otherwise explain all abbreviations at first mention in the abstract and text, except for: DNA, RNA, AIDS, and HIV. Standard SI abbreviations for units do not need to be spelled out. Brief Communications should include an Introduction, Materials and Methods, Results and Discussion sections. Case Reports and Letters to the Editor do not need to include these divisions. Introduction: This should give the reasons for doing the work. As this is a specialist journal a detailed review of the literature is not necessary. The introduction should preferably conclude with a final paragraph stating concisely and clearly the aims and objectives of the investigation. Materials and Methods: A full technical description of a method should be given in detail only when the method is new. Results: This need only report results of representative experiments illustrated by tables and figures. Use well-known statistical tests in preference to obscure ones. Consult a statistician or a statistics text for detailed advice. Discussion (including Conclusions): This section must not recapitulate results but should relate the authors’ experiments to other work and give their conclusions, which may be given in a subsection headed after called Conclusions. References: References are numbered. All publications cited in the text should be presented in a list of references following the text of the manuscript. In the text refer to references by a number
A3
in square brackets on the line (e.g. Since Peterson [1]), and the full reference should be given in a numerical list at the end of the paper. References should be given in the following form: 1. Latagliata R, Concetta Petti M, Mandelli F. Acute myeloid leukemia in the elderly: ‘per aspera ad astra’? Leukemia Res 1999;23:603– 613. 2. Alfrey V. The isolation of subcellular components. In: Brachet J, Mirsky AE, editors. The cell, biochemistry, physiology, morphology I. New York: Academic Press, 1959. p. 200. Note: Authors are strongly encouraged to check the accuracy of each reference against its original source. Work accepted for publication but not yet published should be referred to as ‘in press’. Authors should provide evidence (such as a copy of the letter of acceptance). References concerning unpublished data, theses, and ‘personal communications’ should not be cited in the reference list but may be mentioned in the text. Do not only put the first author et al. list all authors. 5. Acknowledgments should be organized in the following sequence. Acknowledgments—All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgments section. E.g. those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair that provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance. Role of the funding source—All sources of funding should be declared. Authors should declare the role of study sponsors, if any, in the study design, collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. Authors’ Contributions—All authors should have made substantial contributions to the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data. (2) drafting the article or revising it critically for important intellectual content. (3) final approval of the version to be submitted. For authors we use initials and if there is more than one author that does the same function put them together. Note: If there is more than one author that contributed equally to the work it goes in this section not on the title page. Conflict of Interest—All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. E.g. potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/ registrations, and grants or other funding. If there no conflicts of interest exist this must be stated. Please see the Elsevier website for further information http://www.elsevier.com/wps/find/ authorsview.authors/conflictsofinterest. 6. Figures and Figure Legends—Figures should be cited consecutively in the text. Full details for the electronic submission of artwork can be obtained from http://www.elsevier.com/artwor kinstructions. All figures have to be uploaded in EES separately. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions. Type the figure legends in order in one word document and starting with the words figure legends; limit 40 words or less. Spacing is 1.5 and if more than one page put a page number in the footer. 7. Table and Table Legends—Tables should be cited consecutively in the text. Type tables on separate pages with a title. Avoid white spaces in the table by using footnotes, and ensure all symbols or abbreviation are explained. Take care to distinguish between ‘zero’ and ‘not done’ as an entry in the table. Tables are uploaded separately.
A4
Editorial / Leukemia Research Reports 1 (2012) A2–A5
Type the table legends in order in one word document and starting with the words table legends. Spacing is 1.5 and if more than one page put a page number in the footer. Footnotes: Footnotes should only be used to provide addresses of authors or to provide explanations essential to the understanding of Tables. 8. Supplementary Data—As Leukemia Research Reports focuses on short papers, Supplementary Data files are not accepted. Ethics—Identifying information, including patients images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission. Drug names—Use generic names for drugs. Commercial names may be included in parentheses at first mention in the text. Complicated drug names or regimens may be abbreviated, with the abbreviation in parentheses after first mention. Revised Manuscript—All manuscripts are peer-reviewed. On receipt of the first decision letter authors should send their revised manuscript as soon as possible in order to ensure that the scientific content of their manuscript is timely and up to date. The revised paper must be submitted without tracking or highlights and 1.5 spaced. A Revision Letter must contain detailed responses to the reviewers and indicate where in the letter you changed the text. Author Names—This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts: Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include the following: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, and letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum. Copyright—Upon acceptance of an article, authors will be asked to sign a Journal Publishing Agreement. This includes details of the rights that you retain as author (for more information on this and copyright see http://www.elsevier.com/wps/find/ authorsview.authors/authorsrights). An e-mail will be sent to the corresponding author confirming receipt of the manuscript
together with a Journal Publishing Agreement form. Following signature of this form and payment of the Author Fee, case reports will be made universally accessible through -ScienceDirect and through the Journal’s own website, www.lrreports.com. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases; contact Elsevier s Rights Department, Philadelphia, PA, USA: Tel. (þ1) 215 238 7869; Fax (þ1) 215 238 2239; e-mail [email protected]. Requests may also be completed online via the Elsevier homepage (http://www.elsevier.com/locate/permissions). Proofs—One set of page proofs in PDF format will be sent by email to the corresponding author. Elsevier now sends PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 available free from -http://www.adobe. com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: -http://www.adobe. com/products/acrobat/acrrsystemreqs.html#70win. If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received. Language services—Authors who require information about language editing and copyediting services pre- and postsubmission should visit -http://webshop.elsevier.com/language services or our customer support site at -http://support.elsevier. com for more information. Enquiries—Authors can keep a track on the progress of their accepted article, and set up e-mail alerts informing them of changes to their manuscript’s status, by using the ‘Track a Paper’ feature at: http://www.elsevier.com/trackarticle. For privacy, information on each article is password-protected. The author should key in the ‘Our Reference’ code (which is in the letter of acknowledgment sent by the publisher on receipt of the accepted article) and the name of the corresponding author. In case of problems or questions, authors may contact the Author Service Department, E-mail: [email protected] Offprints—The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. & 2012 Elsevier Ltd. All rights reserved—This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd. Please click on User Rights for a summary of how articles published in Leukemia Research Reports can be utilized. Notice—No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or
Editorial / Leukemia Research Reports 1 (2012) A2–A5
operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical)
A5
standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. Thank you for considering Leukemia Research Reports for your submission.
